P10.04 A Budget Impact Analysis for Treatment with Ramucirumab Plus Erlotinib in Metastatic EGFR-Mutated NSCLC in the US
2021 ◽
Vol 16
(3)
◽
pp. S322-S323
J. Nilsson
◽
K. Winfree
◽
C. Molife
◽
D. Bhattacharyya
◽
Y. D'Yachova
◽
...
2019 ◽
Vol 22
(2)
◽
pp. 187-195
◽
2015 ◽
Vol 18
(3)
◽
pp. A280
C. Celestin
◽
T. Wandstrat
◽
C.I. Coleman
2017 ◽
Vol 20
(9)
◽
pp. A424
M Bharmal
◽
SP D'Angelo
◽
H Phatak
2019 ◽
Vol 22
◽
pp. S201-S202
C. Painter
◽
T. Curteis
◽
E. Walker
◽
N.C. Hearmon
2018 ◽
Vol 21
(5)
◽
pp. 542-542
Ws Lane
◽
James Weatherall
◽
Jens Gundgaard
◽
Richard F. Pollock
2003 ◽
Vol 6
(6)
◽
pp. 625
J Hornberger
◽
M Covington
◽
R Luo
◽
Z Wang
2017 ◽
Vol 21
(2)
◽
pp. 144-151
◽
Wendy S. Lane
◽
James Weatherall
◽
Jens Gundgaard
◽
Richard F. Pollock
I. van Oostrum
◽
K. De Lameillieure
◽
T.A. Russell-Smith